PDCD1 and autoimmune disease: As the use of anti-PD-1/PD-L1 monoclonal Abs is extending to various malignancies with unprecedented speed, there is also an unmet need to identify risks and benefits of immune checkpoint blockade therapy in cancer patients with a history of autoimmune disease [8,29].